Venclyxto
Venclyxto combo scores European approval for previously untreated chronic lymphocytic leukaemia
March 13, 2020Medical Communications, Sales and Marketing AbbVie, European Commission, Roche, Venclyxto, pharma
The European Commission has moved to authorise AbbVie and Roche’s B-cell lymphoma-2 (BCL-2) inhibitor Venclyxto (venetoclax) when used in combination …
AbbVie’s Venclyxto pins down CHMP approval for treatment-naive chronic lymphocytic leukaemia
February 3, 2020Sales and Marketing AbbVie, CHMP, EMA, Venclyxto, pharma
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has awarded recommendation to AbbVie’s Venclyxto (venetoclax), …
AbbVie’s Venclyxto combo outclasses chemo in treatment-naive chronic lymphocytic leukaemia
June 5, 2019Research and Development ASCO 2019, AbbVie, Venclyxto, pharma
AbbVie was one of many companies to present new data at this year’s American Society of Clinical Oncology (ASCO) Annual …
Abbvie’s chronic lymphocytic leukaemia drug Venclytxo scores greenlight from NICE
January 18, 2019Medical Communications, Sales and Marketing AbbVie, NHS, NICE, Venclyxto, leukaemia, pharma
A new recommendation from NICE means that thousands of patients in England and Wales will be able to receive Abbvie’s …
AbbVie’s Venclyxto combo beats standard of care in chronic lymphocytic leukaemia
December 3, 2018Research and Development, Sales and Marketing ASH 2018, AbbVie, Cancer, Venclyxto, leukaemia, pharma
AbbVie has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to reveal new data on …
Roche and AbbVie’s leukaemia combo smashes Phase 3 endpoint
September 19, 2017Manufacturing and Production, Research and Development AbbVie, Rituxan, Roche, Venclexta, Venclyxto, leukaemia, pharma, pharmaceutical
Venclexta/Venclyxto (venetoclax), Roche and AbbVie’s oral B-cell lymphoma-2 (BCL-2) inhibitor, successfully met its primary endpoint in Phase 3 trials, providing …
European thumbs up for Abbvie leukaemia drug
December 8, 2016Medical Communications, Sales and Marketing AbbVie, Venclyxto
Abbvie has confirmed its Venclyxto (venetoclax) has been granted marketing authorisation by the European Commission (EC) as a monotherapy for …
